EM1905G "Pulmonary Arterial Hypertension in 2019: From death sentence to chronic disease" (IM GR-053119)
Pulmonary Arterial Hypertension (PAH) has been historically a disease associated with guarded prognosis and limited treatment options. Over last two decades multiple therapies for PAH has been approved and treatment landscape has evolved. The purpose of this session is to discuss improvement in long-term prognosis of PAH with early diagnosis and treatment.
UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.
At the conclusion of this activity, the participant should be able to:
- Define and Classify Pulmonary Hypertension
- Describe pathophysiology of Pulmonary Arterial Hypertension
- Identify patients at risk for PAH and initiate diagnostic work up for PAH
- Discuss commonly available treatment options for PAH
- Review the prognosis of PAH patients in era of modern therapy
Trushil Shah, M.D.
Assistant Professor, Department of Internal Medicine
Division of Pulmonary & Critical Care Medicine
Dr. Shah completed his fellowship training in pulmonary and critical care medicine at Rush University in Chicago, Illinois. He joined UT Southwestern’s Pulmonary & Critical Care Medicine Division in 2016 and currently serves as Assistant Professor Of Internal Medicine. He attends on inpatient pulmonary hypertension service and Medical Intensive Care Unit at Clements University Hospital. Dr. Shah also is an integral part of the pulmonary hypertension program. He is actively involved in multiple multicenter clinical research trials in the field of pulmonary hypertension.
- 1.00 AMA